Annual report [Section 13 and 15(d), not S-K Item 405]

Cover

v3.25.1
Cover - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Apr. 04, 2025
Jun. 30, 2024
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Annual Report true      
Document Transition Report false      
Document Period End Date Dec. 31, 2024      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2024      
Current Fiscal Year End Date --12-31      
Entity File Number 001-36268      
Entity Registrant Name TNF Pharmaceuticals, Inc.      
Entity Central Index Key 0001321834      
Entity Tax Identification Number 22-2983783      
Entity Incorporation, State or Country Code DE      
Entity Address, Address Line One 1185 Avenue of the Americas      
Entity Address, Address Line Two Suite 249      
Entity Address, City or Town New York      
Entity Address, State or Province NY      
Entity Address, Postal Zip Code 10036      
City Area Code (856)      
Local Phone Number 848-8698      
Title of 12(b) Security Shares of Common Stock, par value $0.001 per share      
Trading Symbol TNF      
Security Exchange Name NASDAQ      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company false      
Entity Shell Company false      
Entity Public Float       $ 3,788
Entity Common Stock, Shares Outstanding     10,132,619  
Documents Incorporated by Reference [Text Block] None      
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Entity Listing, Par Value Per Share $ 0.001      
Auditor Firm ID 3523 536    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheet of TNF Pharmaceuticals. Inc. and Subsidiaries (the “Company”) as of December 31, 2024 and the related consolidated statements of comprehensive loss, changes in stockholders’ equity, and cash flows for the year ended December 31, 2024, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.      
Auditor Name Stephano Slack LLC Morison Cogen LLP    
Auditor Location Wayne, Pennsylvania Blue Bell, Pennsylvania